Drug intelligence / Profile preview

ASCT-1201

Development stage: Preclinical
Lead developer: Alcamena Stem Cell Therapeutics
Modality: Cell Therapies
Administration: Intraarticular

Overview

ASCT-1201 is a pre-clinical stage cell therapy being developed by Alcamena Stem Cell Therapeutics for the treatment of autoimmune diseases, specifically refractory inflammatory monoarthritis in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Designed as a once-monthly intra-articular injection, ASCT-1201 acts as a TNF-α antagonist to treat inflamed joints locally. This localized approach aims to eliminate the need for systemic immunosuppression, potentially reducing side effects associated with systemic TNF inhibitors. The therapy exhibits low nanomolar affinity for its target with no reported off-target activity.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on ASCT-1201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASCT-1201.

Explore the full profile